Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 89 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Current ART Clear all

Conditions: Substance-Related Disorders
Interventions: Experimental memory training, Comparator memory training 1, Comparator memory training 2; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Assisted Reproductive Technology, Antibiotic Prophylaxis, Embryo Transfer
Interventions: Withholding antibiotic prophylaxis; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 43 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Posttraumatic Stress Disorder, PTSD
Interventions: Trauma Adaptive Recovery Group Education and Therapy, Enhanced Treatment As Usual; Behavioral
Lead sponsor: UConn Health; Other
Eligibility: 13 Years to 17 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 7
States / cities: East Hartford, Connecticut • Farmington, Connecticut • Hartford, Connecticut + 1 more

Conditions: Hiv
Interventions: FTC/TAF; Drug
Lead sponsor: Philadelphia Fight; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: Elvucitabine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 5
States / cities: Orlando, Florida • Pensacola, Florida • Newark, New Jersey + 2 more

Conditions: HIV/AIDS
Interventions: LinkPositively; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV
Interventions: Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), Feasibility of Intervention Measure (FIM), HIV Stigma Scale Questionnaire, HIV Treatment Satisfaction Questionnaire status version (HIVTSQs12), HIV Treatment Satisfaction Questionnaire change version (HIVTSQc12), Needs and Barriers Assessment, Pre-visit Outreach, Qualitative interview - patient participants, Staff education, Staff Month 7 and 15 Survey - Staff Burden and Engagement, Qualitative interview - staff; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Harlan, Iowa • Shenandoah, Iowa • Grand Island, Nebraska + 1 more

Conditions: HIV Infection
Interventions: Efavirenz; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV Infections
Interventions: CCR5mAb004; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Fort Lauderdale, Florida + 4 more

Conditions: HIV Infections, Lipodystrophy
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: San Diego, California • Baltimore, Maryland • Columbus, Ohio + 1 more

Conditions: Human Immunodeficiency Virus
Interventions: Client-Centered Representative Payee; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 100 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Birmingham, Alabama • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Retinal Disease, Glaucoma, Optic Nerve Diseases
Interventions: Investigational contact OCT system, Investigational noncontact OCT system:; Device
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Antiretroviral therapy; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 16 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Axillary lymph node dissection (ALND), Axillary radiotherapy (ART); Procedure
Lead sponsor: University Hospital, Basel, Switzerland; Other
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 3
States / cities: Bethesda, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome, Fetal Alcohol Effect
Interventions: General information, Baseline brief intervention, Remote online booster sessions, SMS; Other · Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: HIV Infections
Interventions: Cemiplimab, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina

Conditions: Major Depression, Fibromyalgia
Interventions: Active TMS, Sham TMS; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: HIV
Interventions: efavirenz; Drug
Lead sponsor: PENTA Foundation; Network
Eligibility: 8 Years to 24 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV-1-infection
Interventions: PENNVAX-GP, INO-6145, INO-9012, CELLECTRA® 2000; Biological · Device
Lead sponsor: Steven Deeks; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
Interventions: Non-Interventional, Non-Interventional Follow-up; Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 15
States / cities: La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more

Conditions: HIV Infections
Interventions: Tipranavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 28 more

Conditions: HIV Infections
Interventions: Antiretroviral Treatment Interruption; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 17 more

Conditions: HIV, AIDS
Interventions: individualized Texting for Adherence Building (iTAB), Psychoeducation; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stroke, Fatigue, Chronic Stroke, Stroke Sequelae
Interventions: anodal transcranial direct current stimulation (a-tDCS), sham stimulation; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 35 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Charleston, South Carolina

Search by objective public record fields.

Effects of Repeated Memory Training on Memory Function and Addiction Related Processes

Prophylactic Antibiotics Prior to Embryo Transfer (PAPET): RCT

Girls In Recovery From Life Stress (GIRLS) Study

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

LinkPositively: A Technology-Delivered Peer Navigation and Social Networking Intervention to Improve HIV Care

IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs

Impact of Representative Payee Services on ART Adherence Among Marginalized People Living With HIV/AIDS

Optimize Pediatric OCT Imaging

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia

BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection

Therapeutic Vaccination in Treated HIV Disease

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection

Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment

Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users

Post-stroke Fatigue, Inflammation, tDCS